JPH3 Facilitates Cisplatin Resistance in Anaplastic Thyroid Cancer via Activation of the JAK-STAT Signaling Pathway - PubMed
3 hours ago
- #Chemoresistance
- #JAK-STAT Pathway
- #Anaplastic Thyroid Cancer
- JPH3 is highly expressed in thyroid cancer (TC) and linked to shorter patient survival.
- JPH3 acts as an oncogene in anaplastic thyroid cancer (ATC), promoting tumor development.
- JPH3 activates the JAK-STAT signaling pathway via upregulation of COL26A1.
- JPH3 enhances proliferation, invasion, and migration of ATC cells through JAK-STAT activation.
- JPH3 contributes to cisplatin (DDP) resistance in ATC cells via JAK-STAT signaling.
- The study provides insights into chemoresistance mechanisms in aggressive ATC.